Literature DB >> 10965617

Clinical effects of ventricular assist system in end-stage cardiac failure. Advantages of left ventricular blood drainage for recovery from cardiac dysfunction.

S Kyo1, H Tanabe, H Asano, H Ohuchi, H Nogaki, M Ishikawa, Y Yokote, T Koyanagi, H Noda, R Omoto.   

Abstract

OBJECTIVES: Heart transplantation is extremely limited currently in Japan. As a consequence ventricular assist system implantation is employed the patient falls into end-stage cardiogenic shock. This preliminary report describes our initial clinical experience with use of 2 kinds of ventricular assist system for 13 Japanese patients.
METHODS: 7 patients were supported by a left ventricular assist system with blood drainage from the left atrium (LA drainage Group) using a Toyobo ventricular assist system, while another 6 patients were supported by a left ventricular assist system with blood drainage from the left ventricle (LV drainage Group) using the Toyobo ventricular assist system (1 patient) or TCI-LVAS (5 patients).
RESULTS: The average duration of ventricular assist system support in the LV drainage Group was 112 days including two on-going patients (now at 39 days and 241 days) and in the LA drainage Group was 49 days. The average left ventricular ejection fraction at 3 weeks after ventricular assist system implantation was improved from 12.3 to 54% using the TCI-LVAS and from 14 to 33% using the Toyobo ventricular assist system with drainage from the left ventricle. However, this was decreased from 20 to 10% using the Toyobo ventricular assist system with drainage from the left atrium. The ventricular assist system was explanted in 4 patients (31%) with recovery of cardiac dysfunction and 3 were long survivors. The 2 on-going patients are awaiting heart transplantation. Thus the current survival rate overall is 38%. The survival rate (67%) is excellent in the LV drainage Group including 2 long survivors after explantation.
CONCLUSION: Ventricular assist system support with drainage from the left ventricle seems to be more advantageous for cardiac functional recovery than from the left atrium for end-stage heart failure.

Entities:  

Mesh:

Year:  2000        PMID: 10965617     DOI: 10.1007/bf03218172

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  8 in total

1.  One hundred patients with the HeartMate left ventricular assist device: evolving concepts and technology.

Authors:  P M McCarthy; N O Smedira; R L Vargo; M Goormastic; R E Hobbs; R C Starling; J B Young
Journal:  J Thorac Cardiovasc Surg       Date:  1998-04       Impact factor: 5.209

2.  Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery.

Authors:  J J DeRose; J P Umana; M Argenziano; K A Catanese; M T Gardocki; M Flannery; H R Levin; B C Sun; E A Rose; M C Oz
Journal:  J Am Coll Cardiol       Date:  1997-12       Impact factor: 24.094

3.  Successful mechanical circulatory support for more than two years with a left ventricular assist device in a patient with dilated cardiomyopathy.

Authors:  M Loebe; Y Weng; J Müller; M Dandel; R Halfmann; S Spiegelsberger; R Hetzer
Journal:  J Heart Lung Transplant       Date:  1997-11       Impact factor: 10.247

4.  Multi-institutional studies of the National Cardiovascular Center Ventricular Assist System: use in 92 patients.

Authors:  H Takano; Y Taenaka; H Noda; M Kinoshita; A Yagura; E Tatsumi; H Sekii; E Sasaki; M Umezu; T Nakatani
Journal:  ASAIO Trans       Date:  1989 Jul-Sep

5.  Neurohormonal changes after implantation of a left ventricular assist system.

Authors:  R Delgado; B Radovancevic; E K Massin; O H Frazier; C Benedict
Journal:  ASAIO J       Date:  1998 Jul-Aug       Impact factor: 2.872

6.  Improved left ventricular function after chronic left ventricular unloading.

Authors:  O H Frazier; C R Benedict; B Radovancevic; R J Bick; P Capek; W E Springer; M P Macris; R Delgado; L M Buja
Journal:  Ann Thorac Surg       Date:  1996-09       Impact factor: 4.330

7.  HeartMate left ventricular assist device as bridge to heart transplantation.

Authors:  B Koul; J O Solem; S Steen; H Casimir-Ahn; H Granfeldt; U J Lönn
Journal:  Ann Thorac Surg       Date:  1998-06       Impact factor: 4.330

8.  Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure.

Authors:  K Dipla; J A Mattiello; V Jeevanandam; S R Houser; K B Margulies
Journal:  Circulation       Date:  1998-06-16       Impact factor: 29.690

  8 in total
  1 in total

1.  Compact, reliable ventricular assist device as a bridge to recovery or for semipermanent use.

Authors:  K Nishimura; S Kono; T Nishina; K Ueyama; A Ikai; T Ikeda; C Nojiri; T Akamatsu; M Komeda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.